TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05969457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naropeine
Description: Local anesthesia with injection of Ropivacaine (20mL of ropivacaine 7.5 mg/mL, i.e. 150mg)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: questionnaires
Description: Numerical Rating scale Questionnaire FSFI Qustionnaire SF12 Questionnaire DN4

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaires
Description: Numerical Rating scale Questionnaire FSFI Qustionnaire SF12 Questionnaire DN4

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection of 20 mL of NaCl
Study: NCT05996666

Intervention type: DEVICE
Intervention: Liver-cancer early detection test
Description: Blood collection and liver-cancer early detection test

Intervention type: DEVICE
Intervention: Liver-cancer early detection test
Description: Blood collection and liver-cancer early detection test
Study: NCT06379646

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: YTS109
Description: Subjects will receive YTS109 Cell Injection(3E6STAR+T cell/kg) once in this study.
Study: NCT04971200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tildrakizumab
Description: 2 100mg subcutaneous injections Q4W
Study: NCT04445714

Intervention type: DRUG
Group type: OTHER
Intervention: dapagliflozin and saxagliptin
Description: Combination of dapagliflozin and saxagliptin tablet once daily fixed dose combination of Dapa/Saxa 10 mg/5 mg administered orally
Study: NCT05392114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donidalorsen
Description: Donidalorsen will be administered by SC injection.
Study: NCT06510582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab 2 mg/kg
Description: Single 2mg/kg dose of bevacizumab to treat unilateral cSDH

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab 2 mg/kg
Description: Single 2mg/kg dose of bevacizumab to treat unilateral cSDH

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab 4 mg/kg
Description: Two 2mg/kg doses (cumulatively 4mg/kg) of bevacizumab to treat bilateral cSDH

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab 4 mg/kg
Description: Two 2mg/kg doses (cumulatively 4mg/kg) of bevacizumab to treat bilateral cSDH
Study: NCT04995848

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telepalliation
Description: Telepalliation platform Telepal.dk
Study: NCT04889001

Intervention type: OTHER
Group type: OTHER
Intervention: Simulation enhanced HBB training
Description: Simulation enhanced HBB is a one-day course delivered using a format of Explain, Demonstrate and Facilitate practice. Compared to the standard HBB training, the simulation enhanced HBB course is designed with increased peer-to-peer feedback and scripted expert facilitator feedback at HBB practice exercises.
Study: NCT06380946

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iPRF
Description: iPRF has been found to speed up OTM by stimulating the RANK/RANKL/OPG system to initiate osteoclast formation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iPRF
Description: iPRF has been found to speed up OTM by stimulating the RANK/RANKL/OPG system to initiate osteoclast formation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iPRF
Description: iPRF has been found to speed up OTM by stimulating the RANK/RANKL/OPG system to initiate osteoclast formation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iPRF
Description: iPRF has been found to speed up OTM by stimulating the RANK/RANKL/OPG system to initiate osteoclast formation.
Study: NCT05361122

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Maternal Use of Xylitol Chewing Gum During Pregnancy
Description: There are no current interventions within this follow-up study. However, the mothers enrolled in the parent PPaX trial received xylitol-containing chewing gum (1 gram per stick of gum and instructed to chew 1-2 sticks of gum twice daily for a total dose of 2-4 grams/day of xylitol throughout pregnancy starting pre-conception or at \<20 weeks gestation).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Maternal Use of Xylitol Chewing Gum During Pregnancy
Description: There are no current interventions within this follow-up study. However, the mothers enrolled in the parent PPaX trial received xylitol-containing chewing gum (1 gram per stick of gum and instructed to chew 1-2 sticks of gum twice daily for a total dose of 2-4 grams/day of xylitol throughout pregnancy starting pre-conception or at \<20 weeks gestation).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: No Maternal Xylitol Chewing Gum Use During Pregnancy
Description: There are no current interventions within this follow-up study. Children born to mothers who received access to a dentist and prenatal education (oral health, prevention of preterm birth) are in the active comparator group

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: No Maternal Xylitol Chewing Gum Use During Pregnancy
Description: There are no current interventions within this follow-up study. Children born to mothers who received access to a dentist and prenatal education (oral health, prevention of preterm birth) are in the active comparator group
Study: NCT06483373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH7854
Description: SPH7854： Orally, 50-3200mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo：Orally；
Study: NCT06484556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NW-301V
Description: TCR-T T cell targeting KRAS G12V mutation
Study: NCT05807581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical activity
Description: treadmill running 3 times weekly

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: iTBS
Description: repetitive TMS stimulation 5 days weekly for two weeks

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: iTBS
Description: repetitive TMS stimulation 5 days weekly for two weeks
Study: NCT06141330

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D Max Drops
Description: Vitamin D

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin 250 milligram Oral Capsule
Description: Anti Biotic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin 250 milligram Oral Capsule
Description: Anti Biotic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adapalene
Description: Retinoid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene
Description: Retinoid
Study: NCT06430840

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CostCOM (Cost Communication, Financial navigation and counseling)
Description: Patients will receive two 1-hour, phone or video sessions with a remote financial counselor, each session will cover each of these 3 components of CostCOM.~Out-of-pocket cost communication (OOPC): A review of insurance benefits and education of the patient-specific OOPC for anticipated treatment regimen if any (i.e., medication). The OOPC is provided as a total estimate and will be updated at 3-month session in case of changes in treatment or insurance.~Financial navigation: Real-time professional guidance to identify financial assistance programs (e.g., co-pay, living expenses) that alleviate costs of care and discuss information to improve insurance coverage.~Financial counseling: To address the range of patients' financial concerns and enroll patients in financial assistance programs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provision of local and national resources to address financial and social needs
Description: Patients will be provided with a comprehensive list of local resources (in patients' preferred language) in Orange County that can help with food insecurity, ir transportation, as well as contact information for national non-profit organization where patients can self-refer for financial navigation (e.g., Patient Advocate Foundation (PAF)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Education
Description: Patient will receive online and paper educational materials on topics such as health insurance and health insurance literacy, navigating hospitals' price estimator tool.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Patients in all arms will receive usual care, which includes routine oncology visits, use of available ancillary staff, and internal or external resources for co-pay assistance or free medication per normal clinic procedures.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Patients in all arms will receive usual care, which includes routine oncology visits, use of available ancillary staff, and internal or external resources for co-pay assistance or free medication per normal clinic procedures.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Patients in all arms will receive usual care, which includes routine oncology visits, use of available ancillary staff, and internal or external resources for co-pay assistance or free medication per normal clinic procedures.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Screening for financial and social needs
Description: Patients will be screened for financial hardship and health-related social risks.
Study: NCT06484556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NW-301D
Description: TCR-T T cell targeting KRAS G12D mutation
Study: NCT06430840

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening for financial and social needs
Description: Patients will be screened for financial hardship and health-related social risks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening for financial and social needs
Description: Patients will be screened for financial hardship and health-related social risks.
Study: NCT05502705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Intravenous bolus of 1.5 mg/kg of lidocaine followed by a continuous infusion of 3.0 mg/kg for the frst hour, 1.5 mg/kg for the second hour, 0.7 mg/kg until the end of the surgery

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline (NS)
Description: Patients are received equal volumes of saline intravenously until the end of the surgery
Study: NCT05810168

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary modifications
Description: TDA and low FODMAP diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary modifications
Description: TDA and low FODMAP diet
Study: NCT05417880

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Hypoglycemic Agents,Oral
Description: Control group with routine current oral hypoglycemic agents for 3-6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voreta
Description: Empagliflozin 10 mg oral tablets Once Daily for 3-6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voreta plus SunnyD PRO
Description: Empagliflozin 10 mg oral tablets + Vitamin D3 ( 2000 IU ) + Vitamin K2 ( 100 mcg) Once Daily for 3-6 months
Study: NCT06579079

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation Mapping
Description: Implementation mapping is a stakeholder-driven process whereby researchers and practitioners work together to develop an implementation strategy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist Control - Implementation Mapping
Description: Implementation mapping is a stakeholder-driven process whereby researchers and practitioners work together to develop an implementation strategy. Participating schools receiving this treatment will wait one year before developing an implementation strategy for testing.
Study: NCT05836948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-9839
Description: Weekly fixed dose injection of SHR-9839
Study: NCT06451900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: full-term (37 to 41 weeks), Appropriate for gestational age weight between 2500 to 3500 gm infants and with neonatal hyperbilirubinemia not reaching the level of phototherapy were randomised to receive the drug in different doses or in the control group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: full-term (37 to 41 weeks), Appropriate for gestational age weight between 2500 to 3500 gm infants and with neonatal hyperbilirubinemia not reaching the level of phototherapy were randomised to receive the drug in different doses or in the control group

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: ull-term (37 to 41 weeks), Appropriate for gestational age weight between 2500 to 3500 gm infants and with neonatal hyperbilirubinemia not reaching the level of phototherapy were randomised to receive the drug in different doses or in the control group
Study: NCT05753787

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: preservative-free solution of standard post-cataract eye drops
Description: Usage of preservative-free eye drops in comparison to the standard preserved drops with dexamethasone 0.01%.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: preservative-free solution of standard post-cataract eye drops
Description: Usage of preservative-free eye drops in comparison to the standard preserved drops with dexamethasone 0.01%.
Study: NCT06131580

Intervention type: DRUG
Group type: OTHER
Intervention: Intervention/Treatment
Description: Drug: osilodrostat~- osilodrostat, in the form of film coated tablets for oral administration, in the following tablet strengths: 1mg, 5mg, 10mg. Each strength has unique tablet size, colour and imprint.
Study: NCT06208748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezuclastinib in combination with sunitinib
Description: Bezuclastinib in combination with sunitinib (sutent)
Study: NCT05321680

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment withdrawal
Description: Tapering or suspension of antidementia drugs
Study: NCT05035472

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: An initial prophylactic bolus dose of phenylephrine (37.5μg) simultaneous with spinal anesthesia. If the patient did not respond adequately to the current dose (SBP decreased to \< 80% of baseline), the dose was considered to have failed and the subsequent dose for the following patient was increased to the next higher dose level. The dose administered to subsequent patients varied by increments or decrements of 12.5 μg according to the responses of previous patients according to the up-down sequential allocation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: An initial prophylactic bolus dose of norepinephrine (3μg) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 1 μg according to the responses of previous patients according to the up-down sequential allocation.
Study: NCT06070155

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise three time a week
Description: The participants will receive mild to moderate aerobic exercise for three weeks for 12 sessions.
Study: NCT05741957

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Once-a-week Exercise
Description: Participants in this group will participate in a supervised treadmill exercise program delivered by certified fitness instructors. The prescribed program will involve one session weekly for 4 months, and the duration of vigorous-intensity treadmill exercise per session will be 75 min. Participants will exercise with an exercising heart rate at 6-7 metabolic equivalents (METs). Health information provided to the usual care control group will be made available to the participants in this group.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thrice-a-week Exercise
Description: Participants in this group will participate in a supervised treadmill exercise program delivered by certified fitness instructors. The prescribed program will involve three sessions weekly for 4 months, and the duration of vigorous-intensity treadmill exercise per session will be 25 min. Participants will exercise with an exercising heart rate at 6-7 METs. Health information provided to the usual care control group will be made available to the participants in this group.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care Control
Description: Participants in this group will receive health education delivered by research personnel. This program will consist of eight two-hour bi-weekly sessions covering major health issues relating to general health and NAFLD, such as non-communicable diseases, infectious diseases, and a healthy lifestyle.
Study: NCT05052086

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetomotoric ultrasound
Description: Nanoparticles will be injected close to the tumor. Magnetomotoric ultrasound will be performed just before scheduled standard operation, when the patient is anesthetized.
Study: NCT04596202

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supine position
Description: After the infants are treated and fed, they will be given the supine position. After positioning, the residue control will be performed in accordance with the procedure steps guideline at the 30th, 60th and 120th minutes and it will be recorded on residue follow-up form. In addition, the comfort level, heart rate, respiratory rate, and oxygen saturation levels of the infant will be evaluated and recorded at the specified times. At the end of two hours, until the next feeding hour (between 121st-180th minutes), the routine position (supine position) applied in the clinic will be given to the infant and waited in order for physiological parameters and comfort levels to return the period without intervention. The aim here is to ensure for the case to get over the effect of the previous position. No data will be collected within this period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prone position
Description: After the infants are treated and fed, they will be given the prone position. After positioning, the residue control will be performed in accordance with the procedure steps guideline at the 30th, 60th and 120th minutes and it will be recorded on residue follow-up form. In addition, the comfort level, heart rate, respiratory rate, and oxygen saturation levels of the infant will be evaluated and recorded at the specified times. At the end of two hours, until the next feeding hour (between 121st-180th minutes), the routine position (supine position) applied in the clinic will be given to the infant and waited in order for physiological parameters and comfort levels to return the period without intervention. The aim here is to ensure for the case to get over the effect of the previous position. No data will be collected within this period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lateral position
Description: After the infants are treated and fed, they will be given the left or right position. After positioning, the residue control will be performed in accordance with the procedure steps guideline at the 30th, 60th and 120th minutes and it will be recorded on residue follow-up form. In addition, the comfort level, heart rate, respiratory rate, and oxygen saturation levels of the infant will be evaluated and recorded at the specified times. At the end of two hours, until the next feeding hour (between 121st-180th minutes), the routine position (supine position) applied in the clinic will be given to the infant and waited in order for physiological parameters and comfort levels to return the period without intervention. The aim here is to ensure for the case to get over the effect of the previous position. No data will be collected within this period. These processes will continue until the 4 positions are completed. Infants will stay in each position for 2 hours.
Study: NCT05660200

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IBSA Iron ODF
Description: IBSA Iron ODF is a food supplement based on ferric pyrophosphate and folic acid in orodispersible film. IBSA Iron ODF appears as a yellow, opaque, homogeneous film, without visible particles. Once taken, it dissolves on the tongue and can be swallowed without adding water.
Study: NCT05299554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chronocort
Description: Hydrocortisone modified-release capsule 5 mg and 10 mg
Study: NCT06522087

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 40Hz stimulation
Description: Exogenous 40HZ stimulation is a physical intervention that can drive oscillations in the gamma range, and the oscillations and pulses caused at the corresponding frequency can lead to a significant reduction in β-amyloid, reverse tau hyperphosphorylation, and thereby improve the cognitive function of patients.
Study: NCT04691843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Sulfate
Description: Early, high dose, iron supplementation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Sulfate
Description: Early, high dose, iron supplementation
Study: NCT05660200

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: SiderAL® FORTE
Description: Sideral® r.m. contained in SiderAL® FORTE is an iron protected with Sucrosomial® Technology which passes through the gastric environment intact and is absorbed in the intestine, thus preventing any irritation and discomfort to the stomach. The presence of Vitamin C facilitates the absorption of iron.
Study: NCT06573983

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening (Physical Therapy, Gerofit)
Description: Individuals with physical fall risk will be referred to strengthening interventions available within the VHA. These may include Physical Therapy or Gerofit (a supervised exercise program).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (Clinical Psychology, Occupational Therapy)
Description: Individuals with psychological fall risk will be referred psychological interventions such as cognitive behavioral therapy, which focuses on guided talking. This can be performed by VHA occupational therapists and clinical psychologists.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication Reconciliation (Clinical Pharmacology)
Description: Individuals with pharmacological fall risk will be referred to clinical pharmacology for medication reconciliation. This includes examining the current medication list and deprescribing medications, if appropriate.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Safety Modification (Occupational Therapy)
Description: Individuals with environmental fall risk will be referred to occupational therapy for home safety assessments and modifications. This will involve modifying components within the home to reduce potential fall risk factors.